Streptococcus pneumoniae is a primary cause of illness and death among children younger than 5 years in China. The heptavalent pneumococcal conjugate vaccine (PCV7) was the only conjugated vaccine (PCV) available in China from 2008 to 2013. This randomized, controlled, open-label study conducted at 46 Beijing clinics involved 3281 healthy 2-5-year-old Chinese children, randomized 1:1 to receive one dose of the S. pneumoniae heptavalent conjugated vaccine (PCV7) (n = 1643) or Haemophilus influenzae type b conjugate vaccine (Hib) (n = 1638). The main objective of this study was to investigate the impact of PCV7 against that of Hib vaccination in the nasopharyngeal S. pneumoniae colonization in healthy Chinese children. Nasopharyngeal (NP) samples for culture, serotyping and antimicrobial susceptibility testing were collected before vaccination and at Day 60 and 180 post-vaccination. A total 3281 children were enrolled in the study. Demographic characteristics were similar among both study groups: 1641 children received PCV7. Before immunization, S. pneumoniae was isolated in 338 and 360 children in the PCV7 (144 PCV7 isolates) and Hib groups (145 PCV7 isolates), respectively. At Day 180, PCV7 vaccination was more effective than Hib vaccination in reduction NP carriage (20.2% [P = 0.052]) and new acquisition (19.0% [P = 0.066]). When reductions in NP carriage and new acquisition of PCV7 VT plus 6A was analyzed, reduction in the PCV7 vaccinated group achieved statistical significance (P = 0.034 and P = 0.042 versus Hib, respectively). NP carriage of NVT increased in both groups (P = 0.305 between study groups at Day 180). PCV7 decreased NP carriage of non-susceptible VT to amoxicillin (P = 0.000), 
Introduction
Globally, Streptococcus pneumoniae is the most common cause of vaccine-preventable deaths in young children [1] . The World Health Organization (WHO) estimated that in 2008, 0.5 million children died of S. pneumoniae infections [2] . In China, S. pneumoniae is a primary cause of morbidity and mortality among children younger than 5 years [1] : 136,551 cases of severe community-acquired pneumonia and 14,202 deaths were caused by S. pneumoniae in 2010 and 2011, respectively [3] . Nasopharyngeal (NP) colonization by S. pneumoniae is the prerequisite for mucosal and invasive pneumococcal infections [4] . The prevalence of NP colonization varies by season, age, and other genetic and sociological factors. Rates are higher in children younger than 24 months, those whose families have lower socioeconomic status, during winter, and among children who attend daycare centers or who live with multiple siblings [5] [6] [7] . Pneumococcal colonization is usually asymptomatic, but spread from the nasopharynx can lead to sinusitis, otitis media, pneumonia, and invasive diseases such as bacteremia, sepsis and meningitis [2] [8] .
Pneumococcal conjugate vaccines (PCV) reduce pneumococcal disease by preventing: 1) NP acquisition and the duration or density of carriage of S. pneumoniae, and 2) the progression of pneumococcal colonization to disease [4] [9]. The impact of PCVs on pneumococcal NP colonization and carriage is an indicator of efficacy against disease, and has become an important factor for consideration as a supplementary or alternative endpoint in vaccine licensure [9] [10]. The licensure of the heptavalent pneumococcal conjugate vaccine (PCV7) which includes serotypes 4, 6B, 9V, 14, 18C, 19F and 23F in many countries in 2000, reduced the incidence of vaccine-serotype (VT)-associated invasive pneumococcal disease (IPD) by 79% -100% in countries where the vaccine was included in National Immunization Programs [11] [12] . Reducing NP carriage decreases the transmission of VT S. pneumoniae, thereby driving the herd immunity effect observed in unvaccinated individuals where PCV immunization has been implemented [2] [4] [13] . Since most antibiotic non-susceptible S. pneumoniae serotypes are covered by PCV7 [14] , the vaccine also decreases an-
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DOI: 10.4236/wjv.2017. 73003 29 World Journal of Vaccines tibiotic-non-susceptible carriage and disease caused by these VT, leading to a reduction of antimicrobial usage [15] . Due to its effectiveness, WHO recommended that PCV be included in childhood vaccination programs worldwide [13] . However, the use of PCV has led to replacement NP colonization by non-vaccine serotypes (NVT) [16] [17] , and a relative increase in disease caused by antibiotic non-susceptible NVT [14] [18]. Higher-valent PCVs (ten valent vaccine, PCV10 and the 13-valent vaccine, PCV13) are available on the market in various countries although PCV13 is the only one available in the US; however, PCV7 was the only pneumococcal vaccine available in China during the study period [13] . Although estimations and models of the health and economic impact of PCV7 in China have been published [1] [13], the direct effects of PCV7 immunization on NP carriage among children in
China have not yet been described.
The main objectives of this study were to investigate the effectiveness of PCV7 in reducing NP carriage and new acquisition of VT S. pneumoniae in healthy 2-5-year old children in China, and its impact on non-vaccine-type S. pneumoniae (NVT) carriage and pneumococcal antimicrobial susceptibility 6 months after vaccination. Both vaccines were administered as a single dose by intramuscular injection in the lateral deltoid of the upper arm. After vaccination, subjects were observed by trained study staff over 30 minutes for potential reactions.
Methods

Study Design and Definitions
Nasopharyngeal Sampling
NP samples were collected at the clinics by otolaryngologists before vaccination 
Statistical Analyses
Sample size calculation was based on efficacy of carriage prevalence rate on Day A four-fold table χ 2 test was used for inter-group comparisons of categorical variables such as NP carriage and/or resistance rates. P < 0.05 was considered statistically significant.
All statistical analyses were carried out using SPSS 19.0 (SPSS Inc., Chicago, IL).
Results
Population
In total 3281 children were enrolled in the study: 1643 children received PCV7 
Culture
Upon A total of 9284 nasopharyngeal swabs were obtained at all study visits and 2047 S. pneumoniae strains were collected among both study groups for an overall pneumo-coccal detection rate of 22%. Among the 2047 strains, 66 isolates were not included in the analysis as these strains serotype could not be confirmed by reference laboratory.
At baseline (before immunization) (Day 0), S. pneumoniae was isolated in 338 children (21%) and 360 children (22%) in the PCV7 and Hib groups, respectively. Among the S. pneumoniae strains isolated at baseline, 144 isolates (9%) and 145 isolates (9%) in the PCV7 and Hib group, respectively belonged to the serotypes included in the heptavalent pneumococcal conjugate vaccine.
Non-vaccine serotypes were detected at baseline in 11% (180/1643) and 13%
(210/1638) isolates in the PCV7 and Hib group, respectively. Among the non-PCV 7 serotypes (390 isolates), the most common serotypes detected at baseline were 6A (19%), 6C (12.5%), 19A and 15B (7.1% each). 
Effect of Vaccination on Carriage of Pneumococci
The overall S. pneumoniae nasopharyngeal carriage among both study groups remained similar at Day 60 and Day 180. Nasopharyngeal carriage rates at Day 60 and at Day 180 for the PCV 7 group was 20% and 24% respectively, and 21%
and 25% respectively for children randomized to receive Hib vaccine. However, when acquisition rates for serotype 6A were taken into account, the overall new acquisition rate of PCV7 serotypes plus 6A was 9.4% in the PCV7 group and 11.7% in the Hib group representing a 20% reduction in the PCV7 group versus the Hib group (P = 0.042).
On Day 180, 723 S. pneumoniae isolates were culture and tested for antimicrobial susceptibility; 355 isolates in the PCV7 group and 368 isolates in the Hib group. Nasopharyngeal carriage rates of S. pneumoniae that were non-susceptible to these antibiotics were also similar between study groups at baseline. The non-susceptibility and resistance of VT isolates to tested antimicrobials and MDR were compared before and 180 days after PCV7 or Hib vaccination (Figure 1 ). The proportions of VT S. pneumoniae that were non-susceptible to each antibiotic were similar in the PCV7 and Hib groups at Day 0. At Day 180, the proportion of VT isolates that were non-susceptible decreased in the PCV7 group for all antibiotics except for penicillin (which increased from 0 to 1%; not significant). These decreases after PCV7 vaccination were statistically significant for erythromycin, ceftriaxone, ceftriaxone, clindamycin, and MDR S. pneumoniae (P < 0.05) versus Day 0.
By contrast, in the Hib-vaccinated group, the proportion of non-susceptible VT isolates increased by Day 180 for all antibiotics except erythromycin, and le- were statistically significant for amoxicillin (P < 0.001), penicillin and cefuroxime (P < 0.05).
When the non-susceptibility rates among VT isolates at Day 180 were compared between study groups, significantly lower rates were observed in the PCV7 group for penicillin, amoxicillin (P < 0.001), ceftriaxone (P < 0.05) and MDR S. pneumoniae (P < 0.05) versus Hib.
Different impacts on resistance rates to the different antibiotics were observed among VT isolates after PCV7 and Hib vaccination. Before vaccination, the antimicrobial-resistant rates of VT were similar in both study groups. A statistically significant difference in resistance rates between Hib and PCV7 groups was only seen for cefuroxime at this time point (P < 0.001).
At Day 180 after vaccination, the proportion of erythromycin-resistant and clindamycin-resistant VT decreased significantly in the PCV7 group (P < 0.05),
and non-significantly in the Hib group. However, proportions of VT that was resistant to amoxicillin, cefuroxime, ceftriaxone and MDR increased in both study groups, although the increases only reached statistical significance for cefuroxime and MDR (P < 0.05 versus Day 0) in the Hib group. A comparison of
Day 180 VT resistance rates between study groups showed no significant differences.
Discussion
To our knowledge, this is the first report on the impact of a single PCV7 dose on the nasopharyngeal carriage, new acquisition, and antimicrobial susceptibility of S. pneumoniae in a large cohort of 2-5-year-old children in China. This study was designed and completed while PCV7 was the sole PCV registered in China. + 1) in a meta-analysis of studies in which the primary PCV7 dose was given in the first 6 months of life [8] . By contrast, PCV13 serotypes 3 and 19A increased in both groups over this period.
In agreement with previous reports [11] , the children vaccinated with PCV7
had a greater increase in NVT carriage at Day 180 than those vaccinated with Hib, although the difference in overall NVT carriage rates between the study Macrolides and cephalosporins are commonly prescribed by Chinese pediatricians, particularly for respiratory tract infections, and cephalosporin use has increased at tertiary hospitals [26] . PCV7 vaccination led to decreases in nasopharyngeal carriage of VT that were non-susceptible to erythromycin, ceftriaxone, clindamycin, and MDR S. pneumoniae (P < 0.05; Figure 1 (a)) versus Day 0.
Nasopharyngeal carriage of NVT that were non-susceptible to cefuroxime were lower in the PCV7 group than the Hib group at Day 180. This is an important finding, given the high non-susceptibility rates among S. pneumoniae isolated from
Beijing hospitalized children younger than 14 years, of 8.1% for amoxicillin-clavulanic acid, 89.9% for cefuroxime, 99.5% to erythromycin and 20.8% to ceftriaxone during 2013-2014 [22] .
The impact of PCV7 vaccination on antibiotic resistance among VT was more variable. The proportion of VT that was resistant to erythromycin and clindamycin decreased after both PCV7 and Hib vaccination (but significantly after PCV7). However, rates of resistance to amoxicillin, cefuroxime, ceftriaxone and MDR-VT increased in both study groups, with the increases for cefuroxime and MDR-VT significant after Hib vaccination. PCV13 VT isolates 3, 6A and 19A
contributed almost an additional one-fifth of isolates that were non-susceptible and/or resistant to erythromycin before vaccination. This proportion had increased further by Day 180 in the PCV7 group.
Colonization endpoints are important when analyzing data from studies of PCV, because pneumococcal colonization is a precondition for pneumococcal disease [10] . Nasopharyngeal carriage was recently recognized as an important proxy for PCV impact assessments [4] . The one-fifth reduction in S. pneumoniae nasopharyngeal carriage observed in the current study with PCV7 is likely to reduce substantially the burden of VT pneumococcal disease among Chinese A study limitation is that it was conducted in just one city, so the findings cannot necessarily be extrapolated to the rest of the country, particularly for rural areas where PCV7 immunization uptake is even lower [29] . However, the study population was large, and was drawn from all parts of Beijing. Another limitation is that the impact was measured in elder children who are not the routinely recommended population. And the effectiveness may be influenced by previous exposure to the same serotypes compared with younger children who are less possibly colonized. Therefore, we explore that the PCV will induce similar or bigger impact in younger children.
In conclusion, a single dose of PCV7 given to 2-5-year-old children was effec- 
